MX2020005808A - Edición de genes mediante el uso de un adn modificado de extremo cerrado (ceadn). - Google Patents
Edición de genes mediante el uso de un adn modificado de extremo cerrado (ceadn).Info
- Publication number
- MX2020005808A MX2020005808A MX2020005808A MX2020005808A MX2020005808A MX 2020005808 A MX2020005808 A MX 2020005808A MX 2020005808 A MX2020005808 A MX 2020005808A MX 2020005808 A MX2020005808 A MX 2020005808A MX 2020005808 A MX2020005808 A MX 2020005808A
- Authority
- MX
- Mexico
- Prior art keywords
- gene editing
- cedna
- cedna vectors
- ended dna
- modified closed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595328P | 2017-12-06 | 2017-12-06 | |
| US201762607069P | 2017-12-18 | 2017-12-18 | |
| PCT/US2018/064242 WO2019113310A1 (en) | 2017-12-06 | 2018-12-06 | Gene editing using a modified closed-ended dna (cedna) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005808A true MX2020005808A (es) | 2020-10-28 |
Family
ID=66751200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005808A MX2020005808A (es) | 2017-12-06 | 2018-12-06 | Edición de genes mediante el uso de un adn modificado de extremo cerrado (ceadn). |
Country Status (14)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| WO2019066518A2 (ko) * | 2017-09-28 | 2019-04-04 | 주식회사 툴젠 | 혈액응고인자 viii 유전자 역위 보정능의 유전자 가위 시스템으로 구성된 혈우병 치료용 조성물 |
| AU2019221642A1 (en) * | 2018-02-14 | 2020-07-09 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for antibody and fusion protein production |
| CN109022389A (zh) * | 2018-07-19 | 2018-12-18 | 陕西慧康生物科技有限责任公司 | 一种大肠杆菌表达人艾杜糖醛酸-2-硫酸酯酶的生产方法 |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| WO2020097417A1 (en) * | 2018-11-09 | 2020-05-14 | Generation Bio Co. | Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeats |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| CN118813654A (zh) | 2019-08-12 | 2024-10-22 | 生命编辑制药股份有限公司 | Rna指导的核酸酶及其活性片段及变体以及使用方法 |
| WO2021041473A1 (en) * | 2019-08-27 | 2021-03-04 | The Trustees Of Columbia University In The City Of New York | Engineered exosomes for targeted delivery |
| WO2021042045A1 (en) * | 2019-08-30 | 2021-03-04 | The Trustees Of Columbia University In The City Of New York | Methods for scalable gene insertions |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| IL296660A (en) * | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral DNA vectors and their use for therapeutic expression of factor ix |
| JP2023526049A (ja) * | 2020-05-13 | 2023-06-20 | リソジェン | Gm1ガングリオシド-シスおよび他の障害を処置するための組成物および方法 |
| US20230190893A1 (en) * | 2020-07-14 | 2023-06-22 | The Regents Of The University Of California | Compositions and methods for treating an inherited retinal disease |
| MX2023001109A (es) * | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| MX2023003019A (es) * | 2020-09-16 | 2023-05-08 | Generation Bio Co | Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah). |
| CA3191743A1 (en) * | 2020-09-16 | 2022-03-24 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| US20250270545A1 (en) * | 2020-09-29 | 2025-08-28 | Albert-Ludwigs-Universitat Freiburg | Rescue of recombinant adenoviruses by crispr/cas-mediated in vivo terminal resolution |
| CN112481262B (zh) * | 2020-12-04 | 2022-08-19 | 中国农业科学院农业基因组研究所 | 一种基于CRISPR/Cas9基因编辑技术分析增强子细胞生物学功能的方法 |
| CN112852880B (zh) * | 2021-01-28 | 2022-12-06 | 中吉智药(南京)生物技术有限公司 | 一种基于诱导型昆虫细胞生产aav基因药物的方法 |
| AU2022216614B2 (en) | 2021-02-05 | 2026-03-05 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| WO2022198025A2 (en) * | 2021-03-19 | 2022-09-22 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing pfic therapeutics |
| US20240216534A1 (en) * | 2021-04-26 | 2024-07-04 | University Of Massachusetts | Direct raav-mediated in vivo gene editing of hematopoietic stem cells |
| WO2022240806A1 (en) * | 2021-05-11 | 2022-11-17 | Modernatx, Inc. | Non-viral delivery of dna for prolonged polypeptide expression in vivo |
| CA3219160A1 (en) * | 2021-05-20 | 2022-11-24 | Robert Kotin | Genomic safe harbors |
| KR20240012377A (ko) * | 2021-05-28 | 2024-01-29 | 빔 테라퓨틱스, 인크. | 염기 편집기의 자기-불활성화용 조성물 및 방법 |
| WO2023283420A2 (en) * | 2021-07-09 | 2023-01-12 | The Board Of Trustees Of The University Of Illinois | Therapeutic gene silencing with crispr-cas13 |
| US20230084036A1 (en) * | 2021-08-23 | 2023-03-16 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| WO2023069948A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| JP2025500531A (ja) * | 2021-12-27 | 2025-01-09 | グラセル バイオテクノロジーズ(シャンハイ)カンパニー,リミテッド | 細胞改変のための系及び方法 |
| CN120153081A (zh) * | 2022-07-15 | 2025-06-13 | 埃门多生物公司 | Aplp2安全港位点敲入策略 |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| US20240090481A1 (en) * | 2022-09-16 | 2024-03-21 | Joseph Fenton Lawler | Trans-splicing methods and compositions for generation of single sex offspring |
| EP4704901A2 (en) * | 2023-05-01 | 2026-03-11 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Systems and methods to provide therapeutic factor viii using ultrasound-mediated nucleic acid delivery |
| IL327036A (en) * | 2023-09-19 | 2026-05-01 | Poseida Therapeutics Inc | Compositions and methods for combining viral vectors |
| CN122422522A (zh) * | 2023-10-17 | 2026-07-17 | 世代生物公司 | 合成部分单链核酸组合物及其用途和方法 |
| WO2025083617A1 (en) | 2023-10-18 | 2025-04-24 | Nanocell Therapeutics Holdings B.V. | Methods and compositions for nucleic construct delivery |
| WO2025106523A1 (en) * | 2023-11-14 | 2025-05-22 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of f8 expression |
| WO2025106834A1 (en) * | 2023-11-17 | 2025-05-22 | Temple University-Of The Commonwealth System Of Higher Education | A single-plasmid system for enhanced crispr-cas9 mediated homologous recombination |
| WO2026085495A1 (en) | 2024-10-18 | 2026-04-23 | Generation Bio Co. | Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| US10604771B2 (en) * | 2013-05-10 | 2020-03-31 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| CN111206032B (zh) * | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| US20160369258A1 (en) * | 2014-03-11 | 2016-12-22 | University Of Washington | Restricting nuclear protein to specific phases of the cell cycle |
| EP4019635A1 (en) * | 2015-03-25 | 2022-06-29 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
| JP6851319B2 (ja) * | 2015-04-27 | 2021-03-31 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系 |
| WO2016205728A1 (en) * | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
| IL261524B2 (en) * | 2016-03-03 | 2023-10-01 | Univ Massachusetts | End-capped linear double-stranded DNA for non-viral gene transfer |
| CA3075168A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | Modified closed-ended dna (cedna) |
-
2018
- 2018-12-06 JP JP2020531057A patent/JP2021505159A/ja active Pending
- 2018-12-06 WO PCT/US2018/064242 patent/WO2019113310A1/en not_active Ceased
- 2018-12-06 MX MX2020005808A patent/MX2020005808A/es unknown
- 2018-12-06 US US16/769,671 patent/US20220290186A1/en not_active Abandoned
- 2018-12-06 MA MA051113A patent/MA51113A/fr unknown
- 2018-12-06 CA CA3084185A patent/CA3084185A1/en active Pending
- 2018-12-06 CN CN201880083624.0A patent/CN111527200A/zh active Pending
- 2018-12-06 SG SG10202012132WA patent/SG10202012132WA/en unknown
- 2018-12-06 EP EP18886653.7A patent/EP3720952A4/en active Pending
- 2018-12-06 SG SG11202005281XA patent/SG11202005281XA/en unknown
- 2018-12-06 KR KR1020207018991A patent/KR20200093635A/ko not_active Ceased
- 2018-12-06 BR BR112020009858-2A patent/BR112020009858A2/pt not_active Application Discontinuation
- 2018-12-06 AU AU2018378672A patent/AU2018378672A1/en not_active Abandoned
-
2020
- 2020-05-21 IL IL274845A patent/IL274845A/en unknown
- 2020-06-01 PH PH12020550771A patent/PH12020550771A1/en unknown
-
2023
- 2023-11-16 JP JP2023195038A patent/JP2024003220A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220290186A1 (en) | 2022-09-15 |
| IL274845A (en) | 2020-07-30 |
| SG10202012132WA (en) | 2021-01-28 |
| JP2021505159A (ja) | 2021-02-18 |
| BR112020009858A2 (pt) | 2020-11-17 |
| CN111527200A (zh) | 2020-08-11 |
| RU2020121128A (ru) | 2022-01-11 |
| CA3084185A1 (en) | 2019-06-13 |
| MA51113A (fr) | 2020-10-14 |
| SG11202005281XA (en) | 2020-07-29 |
| EP3720952A4 (en) | 2021-09-01 |
| JP2024003220A (ja) | 2024-01-11 |
| AU2018378672A1 (en) | 2020-07-09 |
| KR20200093635A (ko) | 2020-08-05 |
| PH12020550771A1 (en) | 2021-05-10 |
| EP3720952A1 (en) | 2020-10-14 |
| WO2019113310A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550771A1 (en) | Gene editing using a modified closed-ended dna (cedna) | |
| PH12020500465A1 (en) | Modified closed-ended dna (cedna) | |
| PH12021550849A1 (en) | Compositions and methods for immunotherapy | |
| MX2023010271A (es) | Secuenciacion de celulas individuales de alto rendimiento con sesgo de amplificacion reducido. | |
| WO2021055459A8 (en) | Highly efficient dna base editors mediated by rna-aptamer recruitment for targeted genome modification and uses thereof | |
| PH12021551114A1 (en) | Crispr-cas12j enzyme and system | |
| SA518391294B1 (ar) | التحرير المتعدد للجينوم | |
| EP3953477A4 (en) | HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING | |
| IL286324A (en) | Methods and compositions for editing nucleotide sequences | |
| EP4431607A3 (en) | High-throughput precision genome editing | |
| GB2568444A (en) | De novo synthesized nucleic acid libraries | |
| MX391311B (es) | Acidos nucleicos modificados dirigidos a acidos nucleicos. | |
| WO2019236599A3 (en) | High-throughput single-cell transcriptome libraries and methods of making and of using | |
| WO2019090251A3 (en) | Nucleic acid indexing techniques | |
| EP4424824A3 (en) | Nucleic acid-based data storage | |
| HK1200871A1 (en) | Modified dna-binding proteins and uses thereof | |
| MX2021014712A (es) | Polipeptidos de transposasa y sus usos. | |
| EA201991450A1 (ru) | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии | |
| PH12017501834B1 (en) | De novo binding domain containing polypeptides and uses thereof | |
| DK1928901T3 (da) | Polypeptider, der har beta-glucosidaseaktivitet og polynukleotider, der koder for samme | |
| UY34227A (es) | Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo | |
| EP3964575A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| WO2013173774A3 (en) | Molecular inversion probes | |
| EP3966335A4 (en) | Improved gene editing system | |
| IL292004B2 (en) | Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof |